|
Volumn 89, Issue 1, 2011, Pages 17-19
|
Where cost, medical necessity, and morality meet: Should US government insurance programs pay for erectile dysfunction drugs?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
PHOSPHODIESTERASE INHIBITOR;
SILDENAFIL;
TADALAFIL;
VARDENAFIL;
ERECTILE DYSFUNCTION;
GOVERNMENT;
HEALTH CARE COST;
HEALTH CARE FINANCING;
HEALTH CARE POLICY;
HEALTH INSURANCE;
HUMAN;
MEDICAID;
MEDICARE;
MORALITY;
PRIORITY JOURNAL;
REVIEW;
SEXUAL BEHAVIOR;
UNITED STATES;
ERECTILE DYSFUNCTION;
HEALTH CARE REFORM;
HEALTH POLICY;
HUMANS;
INSURANCE COVERAGE;
MALE;
MEDICAID;
MEDICARE PART D;
MORALS;
NATIONAL HEALTH INSURANCE, UNITED STATES;
PHOSPHODIESTERASE 5 INHIBITORS;
UNITED STATES;
|
EID: 78650439048
PISSN: 00099236
EISSN: 15326535
Source Type: Journal
DOI: 10.1038/clpt.2010.179 Document Type: Review |
Times cited : (16)
|
References (10)
|